Novo Nordisk A/S (NVO): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Novo Nordisk A/S ( NVO) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.2%. By the end of trading, Novo Nordisk A/S rose $2.04 (1.2%) to $167.85 on light volume. Throughout the day, 173,630 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 304,300 shares. The stock ranged in a price between $167.00-$168.13 after having opened the day at $167.61 as compared to the previous trading day's close of $165.81. Other companies within the Drugs industry that increased today were: Senesco Technologies ( SNTI), up 56.1%, Gentium SpA ( GENT), up 49.7%, GW Pharmaceuticals PLC ADR ( GWPH), up 24.7% and Idera Pharmaceuticals ( IDRA), up 16.3%.

Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $91.1 billion and is part of the health care sector. Shares are up 1.6% year to date as of the close of trading on Thursday. Currently there is 1 analyst that rates Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 2 rate it a hold.

TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, notable return on equity, expanding profit margins and compelling growth in net income. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front, Mast Therapeutics ( MSTX), down 37.2%, IntelliPharmaCeutics International ( IPCI), down 20.4%, Pernix Therapeutics Holdings ( PTX), down 16.9% and Abaxis ( ABAX), down 16.1% , were all laggards within the drugs industry with ACADIA Pharmaceuticals ( ACAD) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Stocks Waver Amid a Rise in Bond Yields, Strong Earnings

Stocks Waver Amid a Rise in Bond Yields, Strong Earnings

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

Investors Shouldn't Be Worried About Trump's Trade Tariffs: Ian Bremmer

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists

NYSE Suspends Trading for Some Shares of Nasdaq-Listed Amazon, Alphabet

NYSE Suspends Trading for Some Shares of Nasdaq-Listed Amazon, Alphabet

Video: Jim Cramer Reveals Why He's Cautious on Stocks

Video: Jim Cramer Reveals Why He's Cautious on Stocks